BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nab-paclitaxel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nab-paclitaxel\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05429463-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT05429463)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectabl
 e Squamous Cell NSCLC（neoSCORE Ⅱ）\nEstimated primary completion: 30 
 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pa
 clitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05429463
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06725498-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06725498)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Intra-arterial Chemotherapy C
 ombined with Radiotherapy and Immunotherapy for HNSCC\nEstimated primary c
 ompletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06725498
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770113-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07770113)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Random\, Non-controlled\, O
 pen Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclit
 axel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer\nEstim
 ated primary completion: 30 November 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07770113
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02207465-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT02207465)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: A Phase I Dual Dose Escalatio
 n Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and 
 Borderline Resectable Pancreatic Cancer\nEstimated primary completion: Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pacli
 taxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT02207465
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02340117-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT02340117)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Study of Combined SGT-53 Plus
  Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT02340117
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02632305-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT02632305)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Study to See the Effects Th
 at a New Combination of the Three Drugs\, Nab-paclitaxel\, Gemcitabine\, a
 nd Cisplatin Has on Biliary Tract Cancer\nEstimated primary completion: De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pacl
 itaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT02632305
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06538896-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06538896)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Tislelizumab 
 Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-N
 egative Breast Cancer with Bone Metastasis，an Exploratory\, Single-Arm\,
  Multicenter Phase II Clinical Study\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitax
 el#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6538896
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245797-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07245797)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: A Phase II\, 
 Multicenter\, Open-label Study to Evaluate the Efficacy and Safety of Neoa
 djuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcuta
 neous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated\, HER
 2+\, eBC\nEstimated primary completion: 15 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07245797
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747169-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06747169)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin 
 in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small C
 ell Lung Cancer: a Single-arm\, Multicenter Clinical Study\nEstimated prim
 ary completion: 17 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06747169
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793761-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06793761)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Phase II Study to Evaluate 
 the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined wi
 th Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSC
 C\nEstimated primary completion: 20 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06793761
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03606967-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT03606967)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Testing the A
 ddition of an Individualized Vaccine to Durvalumab and Tremelimumab and Ch
 emotherapy in Patients With Metastatic Triple Negative Breast Cancer\nEsti
 mated primary completion: 30 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03606967
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05227664-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05227664)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: A Study of AK
 117/AK112 in Metastatic Triple-Negative Breast Cancer\nEstimated primary c
 ompletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05227664
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06055738-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06055738)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Zimberelimab Combined With Al
 bumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC\nEst
 imated primary completion: 30 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06055738
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646055-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06646055)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: AK112 and Cadonilimab Combi
 ned With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer\nEs
 timated primary completion: 30 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06646055
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07125547-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07125547)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Neoadjuvant Tislelizumab + Na
 b-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer\nEstimate
 d primary completion: 30 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07125547
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126119-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07126119)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Neoadjuvant Tislelizumab in C
 ombination With Nab-Paclitaxel for UTUC\nEstimated primary completion: 30 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pa
 clitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07126119
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07233252-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07233252)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Nephron-sparing Treatment of 
 Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer\nEstimated primary c
 ompletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07233252
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03652428-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT03652428)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: Phase I Nab-Paclitaxel Plus
  Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (L
 APC)\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03652428
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04115163-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04115163)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Biologically Optimized Infusi
 on Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metasta
 tic Pancreatic Cancer\nEstimated primary completion: 31 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04115163
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04894643-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase na readout est. (NCT04894643)
DESCRIPTION:Nab-paclitaxel\, phase na.\nStudy: Preoperative\, Proton- Radio
 therapy Combined With Chemotherapy for Borderline Resectable Pancreatic Ca
 ncer\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04894643
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05969171-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05969171)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Single-center\, Prospective
 \, Two Cohort Study of Surufatinib Combined With AG or AG in the First-lin
 e Treatment of Locally Advanced or Metastatic Pancreatic Cancer\nEstimated
  primary completion: 31 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05969171
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06330337-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06330337)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Effect of Electroacupuncture 
 Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of 
 High-grade Glioma\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06330337
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06802757-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06802757)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Posaconazole 
 Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy 
 in Neoadjuvant Therapy for Triple Negative Breast Cancer\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06802757
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06808971-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06808971)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Adebrelimab Combined With Nab
 -paclitaxel\, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of
  Locally Advanced Resectable GC/GEJ\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclit
 axel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06808971
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454031-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT07454031)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: Intraperitoneal PX in Combina
 tion With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous A
 denocarcinoma\nEstimated primary completion: 31 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07454031
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808853-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07808853)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Node-Sparing Short-Course Rad
 iotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuv
 ant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A 
 Prospective Single-Arm\, Phase II Study\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pa
 clitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07808853
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867392-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07867392)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Neoadjuvant Iparomlimab and T
 uvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal
  Junction Cancer\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07867392
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827055-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05827055)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Proglumide and Chemotherapy f
 or Metastatic Pancreatic Cancer\nEstimated primary completion: January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0582705
 5
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06741644-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06741644)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: A Phase I/II Study of CS200
 9 in Participants With Advanced Solid Tumors\nEstimated primary completion
 : January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-p
 aclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06741644
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06770439-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06770439)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: IBI343 Combined With Chemothe
 rapy in Advanced Pancreatic Cancer\nEstimated primary completion: January 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0677
 0439
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904573-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06904573)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Probiotics in Advanced Urothe
 lial Carcinoma\nEstimated primary completion: 1 January 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06904573
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06345599-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06345599)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: PRaG Therapy in Combination
  With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG St
 udy)\nEstimated primary completion: 10 January 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06345599
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07376629-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07376629)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Study of HB0025 Plus Nab-pa
 clitaxel as First Line Therapy for TNBC\nEstimated primary completion: 15 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pac
 litaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07376629
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05355298-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT05355298)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: ACCENT: AMP945 in Combinati
 on With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer\
 nEstimated primary completion: 1 February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05355298
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06770452-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06770452)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: HRS-4642 With Nimotuzumab and
  Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patie
 nts\nEstimated primary completion: 1 February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06770452
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05497778-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT05497778)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: A Phase 1b Study of Gemcitabi
 ne and Nab-paclitaxel in Combination With IM156 in Patients With Advanced 
 Pancreatic Cancer.\nEstimated primary completion: 2 February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05497778
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492759-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06492759)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: High Dose Rad
 iation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Pa
 tients With PD-L1 Positive Metastatic Triple Negative Breast Cancer\nEstim
 ated primary completion: 12 February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06492759
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07452601-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270225
DTEND;VALUE=DATE:20270226
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07452601)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Time-of-Day of Immunotherapy 
 Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC\nEstimated pr
 imary completion: 25 February 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07452601
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687357-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05687357)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Tislelizumab in Combination W
 ith Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
 \nEstimated primary completion: 28 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05687357
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226856-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07226856)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: BMS-986340 in Combination Wit
 h Nivolumab\, Gemcitabine and Nab-paclitaxel for the Treatment of Metastat
 ic and Recurrent Pancreatic Adenocarcinoma\nEstimated primary completion: 
 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab
 -paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07226856
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03893955-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT03893955)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study to Determine the Safety\, Tolerability\, Pharmacokinetics\, and Pr
 eliminary Efficacy of ABBV-927 With ABBV-368\, Budigalimab (ABBV-181) and/
 or Chemotherapy in Participants With Locally Advanced or Metastatic Solid 
 Tumors\nEstimated primary completion: March 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03893955
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06861894-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06861894)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Active Surveillance After Neo
 adjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC\n
 Estimated primary completion: March 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06861894
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348107-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT07348107)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: ATRA and SDK002 in Combinatio
 n With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Panc
 reatic Ductal Adenocarcinoma.\nEstimated primary completion: March 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07348107
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05422794-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT05422794)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Breast Cancer.\nStudy: Testing the A
 ddition of Anti-Cancer Drug\, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pem
 brolizumab)\, to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patie
 nts With Advanced Triple-Negative Breast Cancer\nEstimated primary complet
 ion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 ab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05422794
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632405-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06632405)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: A Trial of Ca
 mrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurre
 nt TNBC\nEstimated primary completion: 31 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06632405
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07777211-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07777211)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: A Study of GKL-006 Injectio
 n in Patients With Advanced Pancreatic Cancer\nEstimated primary completio
 n: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab
 -paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07777211
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751055-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07751055)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Neoadjuvant Chemoradiotherapy
  Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody fo
 r Locally Advanced Esophageal Cancer\nEstimated primary completion: 1 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxe
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 751055
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06102395-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06102395)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Evaluating the Efficacy and S
 afety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treat
 ment of Local Advanced (LA) HNSCC\nEstimated primary completion: 30 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0610
 2395
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06349967-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06349967)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Nab-paclitaxel Combined With 
 Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Canc
 er\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06349967
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07530445-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07530445)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Phase II Study of Iparomlimab
  and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel an
 d Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary
  Tract Cancer\nEstimated primary completion: 30 April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07530445
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451043-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05451043)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Durvalumab and Tremelimumab i
 n Combination With Propranolol and Chemotherapy for Treatment of Advanced 
 Hepatopancreabiliary Tumors (BLOCKED)\nEstimated primary completion: 1 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 51043
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06939270-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06939270)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: CD73/AXL Targeted HypoSti.C
 AR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors\nEstimate
 d primary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06939270
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07310069-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07310069)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Gemcitabine and Nab-Paclitaxe
 l Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cance
 r\nEstimated primary completion: 1 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07310069
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953999-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270514
DTEND;VALUE=DATE:20270515
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06953999)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: A Phase III Study of Ivonesci
 mab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer\nEstimated 
 primary completion: 14 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06953999
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951997-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06951997)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: QL1706 Plus Chidamide\, AG as
  First-line Treatment for Metastatic Pancreatic Cancer\nEstimated primary 
 completion: 15 May 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06951997
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04859465-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04859465)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Albumin-bound Paclitaxel Comb
 ined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectab
 le Angiosarcoma\nEstimated primary completion: 20 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04859465
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421298-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06421298)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Prospective\, Single-arm\, Phase II Clinical Trial to Evaluate the Effic
 acy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in
  Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell 
 Lung Cancer After Failure of First-line Immunotherapy.\nEstimated primary 
 completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06421298
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432594-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07432594)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Neoadjuvant Aitua (PD-1/CTLA-
 4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade 
 Serous Ovarian Cancer\nEstimated primary completion: 30 May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07432594
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618910-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07618910)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Retlirafusp Alfa Plus Chemoth
 erapy as Neoadjuvant Therapy for Thoracic ESCC\nEstimated primary completi
 on: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-
 paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07618910
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973525-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06973525)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: This Study Ai
 ms to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Impl
 ementing a Dynamic Monitoring-guided Treatment Strategy.\nEstimated primar
 y completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06973525
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04999761-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT04999761)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 AB122 Platform Study\nEstimated primary completion: June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04999761
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metasta
 tic Solid Tumors\nEstimated primary completion: June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05825066-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05825066)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Neoadjuvant Chemotherapy for 
 Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma\nEsti
 mated primary completion: June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05825066
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : Study to Evaluate the Safety\, Tolerability & Efficacy of TNG462 in Comb
 ination in PDAC & NSCLC Patients\nEstimated primary completion: June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06922591
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03907475-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT03907475)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Durvalumab in Combination Wit
 h Chemotherapy in Treating Patients With Advanced Solid Tumors\, DURVA+ Tr
 ial\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03907475
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975475-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06975475)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: SHR-A1811 and
  THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Bra
 in Metastases\nEstimated primary completion: 1 June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06975475
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05420454-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270611
SUMMARY:Nab-paclitaxel: Phase 4 readout est. (NCT05420454)
DESCRIPTION:Nab-paclitaxel\, phase 4\, Breast Cancer.\nStudy: A Study for t
 he Neoadjuvant Treatment of Breast Cancer\nEstimated primary completion: 1
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pacl
 itaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05420454
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07163273-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07163273)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Monthly Alternating NALIRIFOX
  and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenoc
 arcinoma\nEstimated primary completion: 20 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07163273
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04396821-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT04396821)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: A Trial to Evaluate Safety 
 and Tolerability of TST001 in Advanced or Metastatic Solid Tumors\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04396821
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04831320-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04831320)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Nab-Paclitaxel in Combination
  With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Ce
 ll Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor\nEstimated prima
 ry completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04831320
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06182072-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT06182072)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: ProAgio in Pancreatic Ductal 
 Adenocarcinoma (PDAC)\nEstimated primary completion: 30 June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06182072
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06513455-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06513455)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: Irinotecan Liposome，Album
 in Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer\n
 Estimated primary completion: 30 June 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06513455
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668453-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07668453)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: An Open-label\, Single-arm\, 
 Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and
  Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malign
 ancies\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07668453
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05776524-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05776524)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Study of Amplitude-Modulated 
 Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer\nEst
 imated primary completion: July 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05776524
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06576115-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06576115)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Gemcitabine\, Nab-paclitaxel 
 Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagn
 etic Fields) Device to Treat Metastatic Pancreatic Cancer\nEstimated prima
 ry completion: July 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06576115
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07088731-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07088731)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Clinical Study to Evaluate th
 e Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintil
 imab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer\nEstimat
 ed primary completion: July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07088731
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876154-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07876154)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Iparomlimab/Tuvonralimab Comb
 ined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally 
 Advanced Cervical Cancer\nEstimated primary completion: July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07876154
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05420467-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Nab-paclitaxel: Phase 4 readout est. (NCT05420467)
DESCRIPTION:Nab-paclitaxel\, phase 4\, Breast Cancer.\nStudy: A Study for t
 he Adjuvant Treatment of Breast Cancer\nEstimated primary completion: 10 J
 uly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclita
 xel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05420467
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06791148-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06791148)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Low-dose Radiotherapy Combine
 d With Chemotherapy and AK112 as Second-line Treatment in Patients With Ad
 vanced G/GEJ Cancer\nEstimated primary completion: 10 July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06791148
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06748508-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270725
DTEND;VALUE=DATE:20270726
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06748508)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Comparing the Efficacy of Sin
 tilimab Plus Nab-POF Regimen\, Sintilimab Plus XELOX Chemotherapy\, and Le
 nvatinib\, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-neg
 ative\, Metastatic Gastric Cancer\nEstimated primary completion: 25 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06748
 508
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07280377-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07280377)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: A Study in Advanced or Meta
 static Gastrointestinal Cancers Exploring Treatment Combinations With Pela
 reorep and Atezolizumab\nEstimated primary completion: 30 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07280377
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03181100-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT03181100)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Atezolizumab With Chemotherap
 y in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Ca
 ncer\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03181100
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483555-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06483555)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: Basal-like PDAC Treated Wit
 h Gemcitabine\, Erlotinib\, and Nab-paclitaxel\nEstimated primary completi
 on: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-
 paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06483555
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917079-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT06917079)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 BBO-11818 in Adult Subjects With KRAS Mutant Cancer\nEstimated primary com
 pletion: August 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06917079
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139587-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nab-paclitaxel: Phase na readout est. (NCT07139587)
DESCRIPTION:Nab-paclitaxel\, phase na.\nStudy: The Efficacy and Safety of I
 paromlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Pac
 litaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroe
 sophageal Junction Adenocarcinoma\nEstimated primary completion: August 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071395
 87
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444541-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07444541)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: ANO31905 in Combination Wit
 h Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Meta
 static Pancreatic Cancer\nEstimated primary completion: August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07444541
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07046221-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07046221)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Tislelizumab Combined With Ch
 emotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by C
 RT or Surgery\nEstimated primary completion: 1 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07046221
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178171-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT07178171)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Breast Cancer.\nStudy: A Study of QL
 1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment
  of Early-Stage TNBC\nEstimated primary completion: 1 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07178171
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701486-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07701486)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: A Study of More Frequent Do
 sing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly 
 Diagnosed Metastatic Pancreatic Cancer\nEstimated primary completion: 1 Au
 gust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclit
 axel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07701486
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07089199-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07089199)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectab
 le Non-small Cell Lung Cancer : A Prospective\, Single-Arm\, Phase II Stud
 y\nEstimated primary completion: 10 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07089199
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624918-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270829
DTEND;VALUE=DATE:20270830
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05624918)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Study of NovoTTF-200T(P) in
  Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic
  Adenocarcinoma\nEstimated primary completion: 29 August 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05624918
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423326-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06423326)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Gemcitabine\, Cisplatin and N
 ab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Bor
 derline Resectable Pancreatic Cancer\nEstimated primary completion: 31 Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclita
 xel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06423326
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05287308-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nab-paclitaxel: Phase na readout est. (NCT05287308)
DESCRIPTION:Nab-paclitaxel\, phase na\, Breast Cancer.\nStudy: Adjuvant Alb
 umin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study\
 nEstimated primary completion: September 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05287308
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07259317-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07259317)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Relacorilant With Nab-Paclita
 xel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma\
 nEstimated primary completion: September 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07259317
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871461-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07871461)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Utilizing Standard of Care In
 duction Chemotherapy Followed by MR-LINAC Radiotherapy and Surgical Explor
 ation to Improve Resectability Rates in Potentially Resectable Locally Adv
 anced Pancreatic Cancer\nEstimated primary completion: September 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07871461
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253964-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04253964)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small C
 ell Lung Cancer Patients Treated With Chemo/Immunotherapy\nEstimated prima
 ry completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04253964
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05192798-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270910
DTEND;VALUE=DATE:20270911
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05192798)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Albumin-Bound
  Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of
  Relapsed or Metastatic TNBC\nEstimated primary completion: 10 September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05192
 798
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601178-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07601178)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: QUEEN-APPLE: 
 A Single-Arm\, Multicenter\, Prospective Phase II Clinical Study of Iparom
 limab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochlorid
 e and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative 
 Breast Cancer\nEstimated primary completion: 15 September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07601178
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07145931-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07145931)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Neoadjuvant Immunochemotherap
 y and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell
  Carcinoma Invading the Skull Base\nEstimated primary completion: 20 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclit
 axel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07145931
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178340-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07178340)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Perioperative Therapy for HER
 2-negative Hepatoid Adenocarcinoma of Stomach\nEstimated primary completio
 n: 20 September 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07178340
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532331-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT06532331)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: A PhaseⅠStudy of ONO-7475 i
 n Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP)\, th
 e Standard of Care\, and ONO-7475 in Combination With GnP in Patients With
  Pancreatic Cancer\nEstimated primary completion: 30 September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06532331
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06662669-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06662669)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: YL-13027 and/or HY-0102 Com
 bined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer\nEstim
 ated primary completion: 30 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06662669
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07317609-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT07317609)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: Neoadjuvant Immunotherapy Com
 bined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal
  Cancer (Endosurgery-02)\nEstimated primary completion: 30 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07317609
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02921022-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nab-paclitaxel: Phase na readout est. (NCT02921022)
DESCRIPTION:Nab-paclitaxel\, phase na.\nStudy: Study Of Gemcitabine\, Nab-p
 aclitaxel\, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
 \nEstimated primary completion: October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT02921022
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03492671-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT03492671)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Testing the Combination of Tw
 o Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized 
 Pancreatic Cancer\nEstimated primary completion: October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03492671
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561685-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT06561685)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tum
 ors\nEstimated primary completion: October 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06561685
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140393-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07140393)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: A Study of HRS-4508 in Comb
 ination With Other Anti-tumor Therapy for Solid Tumor\nEstimated primary c
 ompletion: October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07140393
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296341-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07296341)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: HRS-4642 Combination With O
 ther Antitumor Therapies in Patients With Solid Tumors\nEstimated primary 
 completion: October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07296341
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05562297-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05562297)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Neoadjuvant/Adjuvant Sintilim
 ab\, Nab-paclitaxel\, and Gemcitabine for Resectable/Borderline Resectable
  Pancreatic Cancer\nEstimated primary completion: 1 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05562297
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04940286-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04940286)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Gemcitabine\, Nab-paclitaxel\
 , Durvalumab\, and Oleclumab Before Surgery for the Treatment of in Resect
 able/Borderline Resectable Primary Pancreatic Cancer\nEstimated primary co
 mpletion: 30 October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04940286
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04266249-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04266249)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: CompassHER2-p
 CR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery C
 hemo and Targeted Therapy\nEstimated primary completion: 31 October 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04266249
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06604351-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06604351)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With
  Central Airway Obstruction\nEstimated primary completion: 31 October 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06604351
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828756-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07828756)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Albumin-bound Paclitaxel (Ⅱ
 )-Combined Regimens for Pancreatic Cancer\nEstimated primary completion: 3
 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-p
 aclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07828756
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678593-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07678593)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: A Study of GFH276 Combined 
 With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancr
 eatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation\nEstimated prima
 ry completion: November 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07678593
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05881525-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT05881525)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: NY-ESO-1 TCR-T Cells for NY-E
 SO-1 Positive Subjects With Advanced Solid Tumors\nEstimated primary compl
 etion: 10 November 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05881525
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04297605-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT04297605)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatme
 nt for Patients With Locally Advanced or Metastatic Non-small Cell Lung Ca
 ncer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 
 2\nEstimated primary completion: 30 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04297605
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261683-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07261683)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Phase II Study of Weekly Pacl
 itaxel/Nab-Paclitaxel\, Pembrolizumab\, and Mirabegron for Recurrent Ovari
 an Cancer\nEstimated primary completion: 30 November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07261683
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05026905-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05026905)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Phase II Randomized Study o
 f Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxa
 liplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer\nE
 stimated primary completion: December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05026905
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431270-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-CD73 m
 Ab\, Administered Alone and in Combination With a PD-1 Inhibitor or Chemot
 herapy (the MORNINGSTAR Study)\nEstimated primary completion: December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0543127
 0
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482893-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT05482893)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: Spevatamig (PT886) as Monot
 herapy or in Combination With Chemo and/or Targeted Therapy and/or ICI\, f
 or the Treatment of Patients With Advanced Gastrointestinal Cancers\, Incl
 uding Gastric\, Gastroesophageal Junction\, Pancreatic Ductal or Biliary T
 ract Carcinomas (the TWINPEAK Study)\nEstimated primary completion: Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitax
 el#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5482893
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582538-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05582538)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Restoring Sen
 sitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploi
 ting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel\n
 Estimated primary completion: December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05582538
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06639724-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT06639724)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: Perioperative Fostamatinib Wi
 th Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06639724
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906341-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06906341)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Relacorilant in Combination W
 ith Different Treatment Regimens in Patients With Gynecological Cancers\nE
 stimated primary completion: December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06906341
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255404-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07255404)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Clinical Trial Testing the 
 Safety of Pumitamig (an Investigational Drug) and How Well it Works When C
 ombined With Chemotherapy for People Who Have Not Been Treated Yet for Pan
 creatic Cancer\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07255404
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296705-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07296705)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Neoadjuvant Zanidatamab + Tis
 lelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positi
 ve MIBC\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07296705
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923396-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT07923396)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: GK01 Cell Therapy in Gastric 
 Cancer With Peritoneal Metastasis\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0792
 3396
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06115499-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT06115499)
DESCRIPTION:Nab-paclitaxel\, phase 2/3.\nStudy: The PLATINUM Trial: Optimiz
 ing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PA
 LB2-Associated Metastatic Pancreatic Cancer\nEstimated primary completion:
  1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab
 -paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06115499
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200947-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07200947)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients Wit
 h SMARCA4-Deficient\, Locally Advanced or Metastatic Non-Small Cell Lung C
 ancer.\nEstimated primary completion: 1 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07200947
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307443-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07307443)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Phase II Study of Anlotinib
  and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient\, Loca
 lly Advanced or Metastatic Lung Cancer.\nEstimated primary completion: 1 D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pac
 litaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07307443
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06177522-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06177522)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Adebrelimab Combined With Che
 motherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer\nEstimat
 ed primary completion: 30 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06177522
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018063-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07018063)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Neoadjuvant Nab-Paclitaxel Pl
 us Oxaliplatin\, S-1\, and Sintilimab in Early-Onset Resectable Gastric Ca
 ncer\nEstimated primary completion: 30 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07018063
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253662-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT07253662)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: Pressurized Intraperitoneal A
 erosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis Fro
 m Pancreatic Adenocarcinoma\nEstimated primary completion: 30 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0725366
 2
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07272109-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07272109)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Active Anti-diabetic Treatmen
 t Plus Chemotherapy for Pancreatic Cancer Related Diabetes\nEstimated prim
 ary completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07272109
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04528680-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT04528680)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: Ultrasound-based Blood-brai
 n Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurre
 nt Glioblastoma\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04528680
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683315-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04683315)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: PurIST Classification-Guided 
 Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspir
 ation Samples\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04683315
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Fudan Univers
 ity Shanghai Cancer Center Breast Cancer Precision Platform Series Study- 
 Neoadjuvant Therapy\nEstimated primary completion: 31 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06229496-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT06229496)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: Dose Escalation and Dose Expa
 nsion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06229496
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06569225-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06569225)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Gemcitabine/Cisplatin/Nab-Pac
 litaxel and Rilvegostomig in Resectable iCCA\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 ab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06569225
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Study of Precision Treatment 
 for Rare Tumours in China Guided by PDO and NGS\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06692491
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849492-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06849492)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: HIM Typing Gu
 ides the Treatment of Advanced First-Line Triple-Negative Breast Cancer\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06849492
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06869213-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06869213)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Single-arm\, Open\, Single-
 center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Che
 motherapy for the Perioperative Treatment of Locally Advanced Resectable E
 sophageal Squamous Carcinoma\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068692
 13
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06964906-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06964906)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant H
 igh-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chem
 otherapy for ER-Positive /HER2-Negative Breast Cancer\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06964906
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281976-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07281976)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Breast Cancer.\nStudy: A Trial of 
 LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative B
 reast Cancer\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07281976
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410169-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07410169)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer
 .\nStudy: Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Na
 b-paclitaxel-Induced Peripheral Neuropathy\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab
 -paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07410169
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07705919-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07705919)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: DCE-MRI for Neoadjuvant Tre
 atment Assessment in Patients With Borderline Resectable Pancreatic Cancer
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07705919
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733830-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07733830)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Comparing ICI Followed By CCR
 T And CCRT Followed By Immunotherapy In Unresectable LA-ESCC\nEstimated pr
 imary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07733830
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806110-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07806110)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Gemcitabine and Albumin-Bound
  Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-17
 01 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreat
 ic Cancer\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07806110
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890506-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07890506)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Chidamide Combined With Benme
 lstobart\, Nab-paclitaxel\, and SBRT as Second-Line Treatment for Advanced
  BTC\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07890506
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07928362-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase na readout est. (NCT07928362)
DESCRIPTION:Nab-paclitaxel\, phase na.\nStudy: A Multicenter\, Prospective 
 Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab a
 nd AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07928362
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771622-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06771622)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: Safety and Efficacy of HCB1
 01 in Combination With Multiple Agents in Patients With Advanced Solid Tum
 ors\nEstimated primary completion: 1 January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06771622
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07547332-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07547332)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Nab-Paclitaxel Combined With 
 Local Therapy in Relapsed SCLC\nEstimated primary completion: 1 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075473
 32
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595770-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07595770)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Adebrelimab Combined With Neo
 adjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma\nEstimat
 ed primary completion: 1 January 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07595770
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024615-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT07024615)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: A Study of ASP2138 Given Befo
 re Surgery\, Then Chemotherapy After Surgery\, in People With Pancreatic D
 uctal Cancer\nEstimated primary completion: 31 January 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07024615
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284836-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07284836)
DESCRIPTION:Nab-paclitaxel\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplati
 n (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients W
 ith Liver Metastases After Failure of Standard Therapy\nEstimated primary 
 completion: 31 January 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07284836
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678580-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07678580)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Neoadjuvant Short-Course Radi
 otherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectabl
 e Esophageal Squamous Cell Carcinoma\nEstimated primary completion: 31 Jan
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclit
 axel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07678580
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06393400-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT06393400)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: CHemotherapy And Stool Transp
 lant in PDAC (CHASe-PDAC)\nEstimated primary completion: February 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06393400
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06586515-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT06586515)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 MOONRAY-01\, A Study of LY3962673 in Participants With KRAS G12D-Mutant So
 lid Tumors\nEstimated primary completion: March 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06586515
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483554-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07483554)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: IBI343 in Combination Therapy
  for Advanced Malignant Solid Tumors\nEstimated primary completion: 31 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitax
 el#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7483554
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07458347-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT07458347)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Particip
 ants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Ho
 molog (KRAS) Mutation\nEstimated primary completion: April 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07458347
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491445-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07491445)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Study of Daraxonrasib and Dar
 axonrasib + GnP as First-line Treatment in Patients With Metastatic Pancre
 atic Adenocarcinoma\nEstimated primary completion: April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07491445
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601737-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07601737)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Nimotuzumab Combined With Imm
 unotherapy and Chemotherapy in the Treatment of Locally Advanced Head and 
 Neck Squamous Cell Carcinoma\nEstimated primary completion: 30 April 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07601737
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07076212-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07076212)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Evaluating NALIRIFOX vs Modif
 ied Gemcitabine\, Nab-Paclitaxel and Cisplatin in Patients With Locally Ad
 vanced and Metastatic Pancreatic Adenocarcinoma\nEstimated primary complet
 ion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pa
 clitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07076212
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682376-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07682376)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Low-Dose Radiotherapy With Re
 tlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Loca
 lly Advanced Esophageal Squamous Cell Carcinoma\nEstimated primary complet
 ion: 30 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab
 -paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07682376
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06361888-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT06361888)
DESCRIPTION:Nab-paclitaxel\, phase 2/3.\nStudy: A Phase II/III Trial to Eva
 luate the Efficacy and Safety of Surufatinib Combined With Camrelizumab\, 
 Nab-paclitaxel\, and Gemcitabine in Metastatic Pancreatic Cancer\nEstimate
 d primary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06361888
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493993-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07493993)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Clinical Study on the Efficac
 y and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-P
 aclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophagea
 l Squamous Cell Carcinoma\nEstimated primary completion: 31 May 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07493993
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04543071-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04543071)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Chemo4METPANC Combination Che
 mokine Inhibitor\, Immunotherapy\, and Chemotherapy in Pancreatic Adenocar
 cinoma\nEstimated primary completion: June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04543071
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05502237-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT05502237)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pemb
 rolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Smal
 l Cell Lung Cancer\nEstimated primary completion: June 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05502237
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441890-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06441890)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: BRE-10: Bioma
 rker Optimization of Neoadjuvant Therapy in Breast Cancer\nEstimated prima
 ry completion: June 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06441890
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845786-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07845786)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic S
 quamous Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 
 15 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pac
 litaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07845786
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235202-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280622
DTEND;VALUE=DATE:20280623
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07235202)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: A Study of MR001 Combined W
 ith Chemotherapy in Patients With Locally Advanced or Metastatic Pancreati
 c Ductal Adenocarcinoma (PDAC) After First-line Therapy\nEstimated primary
  completion: 22 June 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07235202
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04241276-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280629
DTEND;VALUE=DATE:20280630
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04241276)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Randomised Trial of ATRA in
  a Novel Drug Combination for Pancreatic Cancer\nEstimated primary complet
 ion: 29 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/na
 b-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04241276
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07057427-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07057427)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Breast Cancer.\nStudy: Efficacy of N
 ab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast 
 Cancer\nEstimated primary completion: 30 June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07057427
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07533305-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07533305)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Efficacy and Safety of QL1706
  Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanc
 ed or Metastatic Esophageal Squamous Cell Carcinoma\nEstimated primary com
 pletion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07533305
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767994-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07767994)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: AK112 Combined With GAP Conve
 rsion Therapy for Locally Advanced Gallbladder Cancer\nEstimated primary c
 ompletion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07767994
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855757-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nab-paclitaxel: Phase na readout est. (NCT07855757)
DESCRIPTION:Nab-paclitaxel\, phase na.\nStudy: Retlirafusp Alfa Plus SOX an
 d Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Mali
 gnant Ascites\nEstimated primary completion: 30 June 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07855757
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043270-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07043270)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: 24BRO681 : Alternating Gnp an
 d mFOLFIRINOX for BR-PDAC\nEstimated primary completion: 1 July 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07043270
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06145308)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Precision Treatment of Recurr
 ent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing\nEstima
 ted primary completion: 10 July 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752550-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07752550)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Retlirafusp A
 lfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast C
 ancer\nEstimated primary completion: 30 July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07752550
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800587-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05800587)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer\nEst
 imated primary completion: 1 August 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05800587
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492680-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07492680)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Study of Navlimetostat (BMS
 -986504) Monotherapy and in Combination With Other Agents in Participants 
 With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion
  (MountainTAP-5)\nEstimated primary completion: 15 August 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07492680
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07457346-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07457346)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Study Testing Emactinib Sul
 fate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head 
 and Neck Cancer\nEstimated primary completion: 30 August 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07457346
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05613413-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05613413)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for 
 Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)\nEs
 timated primary completion: September 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05613413
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07049055-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07049055)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: A Clinical Trial to Evaluat
 e EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic C
 ancer\nEstimated primary completion: September 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07049055
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361991-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07361991)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: IBI363 Plus Bevacizumab Wit
 h or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric 
 Cancer\nEstimated primary completion: September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07361991
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07436741-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07436741)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Surufatinib Plus Gemcitabine 
 and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Ther
 apy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer\
 nEstimated primary completion: September 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07436741
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793942-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280926
DTEND;VALUE=DATE:20280927
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07793942)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Clinical Trial of MK-2010 A
 lone and With Other Treatments in Participants With Advanced Solid Tumors 
 (MK-2010-002)\nEstimated primary completion: 26 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07793942
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445062-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06445062)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: Study of RAS(ON) Inhibitors
  in Patients With Gastrointestinal Solid Tumors\nEstimated primary complet
 ion: 30 September 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06445062
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904378-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06904378)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: ONT01 and Gemcitabine/Nab-p
 aclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocar
 cinoma\nEstimated primary completion: 30 September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06904378
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328802-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07328802)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Exploration of Sintilimab + B
 evacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Adva
 nced/Metastatic Cholangiocarcinoma\nEstimated primary completion: 30 Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclit
 axel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07328802
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582265-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT05582265)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Tislelizumab Combined With Ch
 emotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head 
 and Neck Squamous Cell Carcinoma (REDUCTION-I)\nEstimated primary completi
 on: October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab
 -paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05582265
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07906587-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07906587)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Locally Advanced Resectable H
 ead and Neck Squamous Cell Carcinoma: A Prospective\, Single-Arm Clinical 
 Study\nEstimated primary completion: October 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07906587
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05285358-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281011
DTEND;VALUE=DATE:20281012
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT05285358)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: Pressurized Intraperitoneal A
 erosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin fo
 r the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastase
 s\nEstimated primary completion: 11 October 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05285358
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223047-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07223047)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A Study to Evaluate the Safety\, Tolerability\, and Efficacy of BMS-9865
 23 Alone and in Combination With Anti-Cancer Agents in Participants With A
 dvanced Solid Malignancies\nEstimated primary completion: 13 October 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07223047
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812467-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07812467)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Rimegepant-Sensitized Neoadju
 vant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma\
 nEstimated primary completion: 31 October 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07812467
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06037980-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT06037980)
DESCRIPTION:Nab-paclitaxel\, phase 2/3.\nStudy: CisPlatin plUs Gemcitabine 
 and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Rese
 ction in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk
  for Recurrence\nEstimated primary completion: December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06037980
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tu
 mors\nEstimated primary completion: December 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07475234-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07475234)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: Rimegepant Combined With AG
  Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Ade
 nocarcinoma\nEstimated primary completion: December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07475234
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07864571-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07864571)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Trial of First-line Gemcitabi
 ne and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic C
 ancer\nEstimated primary completion: December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07864571
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06894459-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06894459)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Prospective\, Multicenter\,
  Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoper
 ative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chem
 otherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Ca
 rcinoma\nEstimated primary completion: 1 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06894459
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382559-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT05382559)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: A Study of ASP3082 in Adults 
 With Advanced Solid Tumors\nEstimated primary completion: 31 December 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05382559
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340398-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07340398)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Neoadjuvant T
 rastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel\, Carboplatin\, Tra
 stuzumab\, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER
 2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breas
 t Cancer\nEstimated primary completion: 31 December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07340398
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610629-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07610629)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Retlirafusp Alfa Combined Wit
 h Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gast
 roesophageal Junction Cancer\nEstimated primary completion: 31 December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076106
 29
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622797-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07622797)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Exploratory Clinical Study of
  Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-prese
 rving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Ca
 rcinoma\nEstimated primary completion: 31 December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07622797
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07875907-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT07875907)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: Repurposing Mefloquine for Pa
 ncreatic Cancer Treatment\nEstimated primary completion: January 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07875907
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06897644-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06897644)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Gemcitabine Plus Nab-paclitax
 el as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st
  Line Chemotherapy in Patients With Advanced Pancreatic Cancer.\nEstimated
  primary completion: 1 January 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06897644
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802184-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07802184)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: GnP Combined With SHR-1701 
 and Apatinib as First-Line Treatment for Metastatic PDAC\nEstimated primar
 y completion: 1 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07802184
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885709-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07885709)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC\n
 Estimated primary completion: 1 January 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07885709
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07948317-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07948317)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Camrelizumab Plus Nab-Paclita
 xel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer
 : a Randomized Phase III Trial\nEstimated primary completion: 1 January 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079483
 17
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06422143-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290112
DTEND;VALUE=DATE:20290113
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06422143)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT
 \; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-
 2870-023]\nEstimated primary completion: 12 January 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06422143
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06675136-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290114
DTEND;VALUE=DATE:20290115
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT06675136)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: Nab-Paclitaxel PIPAC in Combi
 nation With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer
  With Peritoneal Metastases\nEstimated primary completion: 14 January 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06675136
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07831330-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07831330)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Albumin-bound Paclitaxel (II)
  in Combination With Gemcitabine as First Line Therapy for Metastatic Panc
 reatic Cancer\nEstimated primary completion: 31 January 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07831330
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996782-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06996782)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nEstimated primar
 y completion: 23 February 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06996782
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578337-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07578337)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Clinical Study Evaluating a
  New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who H
 ave Not Received Prior Treatment for Advanced Disease.\nEstimated primary 
 completion: 28 February 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07578337
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07377045-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT07377045)
DESCRIPTION:Nab-paclitaxel\, phase 1.\nStudy: Clinical Trial of OMTX705 in 
 Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients W
 ith Advanced/Metastatic Pancreatic Adenocarcinoma\nEstimated primary compl
 etion: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/na
 b-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07377045
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463313-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07463313)
DESCRIPTION:Nab-paclitaxel\, phase 2/3.\nStudy: 6 vs 3 Cycles of Neoadjuvan
 t Chemotherapy for Potentially Resectable Locally Advanced Thymic Epitheli
 al Tumors\nEstimated primary completion: March 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07463313
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06323369-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290325
DTEND;VALUE=DATE:20290326
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06323369)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Tislelizumab Combined With Ch
 emotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clini
 cally Node-negative Head and Neck Squamous Cell Carcinoma\nEstimated prima
 ry completion: 25 March 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06323369
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616362-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07616362)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Personalize (Signature Driven
 ) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline P
 ancreatic Ductal Adenocarcinoma.\nEstimated primary completion: April 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07616362
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699757-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT07699757)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion\nEstimat
 ed primary completion: April 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07699757
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07538193-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Nab-paclitaxel: Phase na readout est. (NCT07538193)
DESCRIPTION:Nab-paclitaxel\, phase na\, Non-Small Cell Lung Cancer.\nStudy:
  Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage I
 II Lung Cancer\nEstimated primary completion: May 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07538193
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665684-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07665684)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: Samuraciclib in Combination
  With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pa
 ncreatic Cancer\nEstimated primary completion: May 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07665684
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845565-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07845565)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: FMT Plus SHR-1701 With Nab-Pa
 clitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metas
 tatic Pancreatic Ductal Adenocarcinoma\nEstimated primary completion: May 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0784
 5565
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527806-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07527806)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: Optimization 
 of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer 
 Based on HER2-PET/CT Molecular Imaging\nEstimated primary completion: 1 Ma
 y 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxe
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 527806
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07374003-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290620
DTEND;VALUE=DATE:20290621
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07374003)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Ipromlimab and Tuvonralimab C
 ombined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therap
 y for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma\nEsti
 mated primary completion: 20 June 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07374003
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221474-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07221474)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemothe
 rapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)\nEstimat
 ed primary completion: 2 July 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07221474
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06214572-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290721
DTEND;VALUE=DATE:20290722
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT06214572)
DESCRIPTION:Nab-paclitaxel\, phase 2/3.\nStudy: Radiation Therapy in Unrese
 ctable Gall Bladder Cancer\nEstimated primary completion: 21 July 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06214572
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738341-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07738341)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer
 .\nStudy: GB268 Monotherapy or Combination Therapy for Locally Advanced/Me
 tastatic Breast Cancer (Phase Ib/Ⅱ)\nEstimated primary completion: 1 Aug
 ust 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclita
 xel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07738341
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563738-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07563738)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A 2-part Phase 1/2 Open-label Trial on ODM-212\nEstimated primary comple
 tion: September 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07563738
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06662877-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT06662877)
DESCRIPTION:Nab-paclitaxel\, phase 2/3.\nStudy: Anlotinib Plus Nab-Paclitax
 els and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line
  Treatment\nEstimated primary completion: 1 September 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06662877
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892953-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04892953)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polypr
 ogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy\nEst
 imated primary completion: 30 September 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04892953
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06647563-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06647563)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Neoadjuvant Toripalimab + Che
 motherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Car
 cinoma (Neo-ICT)\nEstimated primary completion: 30 September 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06647563
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283705-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07283705)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Phase II Study Evaluating B
 MS-986504 in MTAP-deleted Pancreatic Cancer\nEstimated primary completion:
  1 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-
 paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07283705
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06869226-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06869226)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Multicenter Phase II Clinic
 al Study of Neoadjuvant Use of Camrelizumab in Combination With Chemothera
 py for Organ Preservation in Esophageal Cancer\nEstimated primary completi
 on: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06869226
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998940-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06998940)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Studying Chemotherapy With or
  Without Panitumumab for Unresectable\, Locally Advanced\, or Metastatic P
 ancreatic Cancer Without KRAS Mutations\nEstimated primary completion: 31 
 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pa
 clitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06998940
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07640295-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07640295)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: Study of JAB-23E73 in Combi
 nation With Chemotherapy in Participants With Metastatic PDAC Harboring KR
 AS Gene Alterations\nEstimated primary completion: 31 December 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07640295
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904442-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07904442)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Application of Intraperitonea
 l Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Perito
 neal Metastasis\nEstimated primary completion: 31 December 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07904442
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07934927-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07934927)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: A Phase II Study of Nab-Pacli
 taxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advance
 d Mucosal Melanoma\nEstimated primary completion: 31 December 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07934927
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06607185-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT06607185)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Muta
 nt Solid Tumors\nEstimated primary completion: January 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06607185
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745882-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06745882)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Prospective Trial Assessing Real World Outcomes Response to Pembro in Blac
 k Patients w/ NSCLC\nEstimated primary completion: January 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06745882
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662395-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20300124
DTEND;VALUE=DATE:20300125
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07662395)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy
 : SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lu
 ng Cancer\nEstimated primary completion: 24 January 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07662395
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748611-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20300203
DTEND;VALUE=DATE:20300204
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07748611)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: SMAD4 Tailored Neoadjuvant Th
 erapy for the Treatment of Resectable and Borderline Resectable Pancreatic
  Ductal Adenocarcinoma\, SMART-PANC Trial\nEstimated primary completion: 3
  February 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-p
 aclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07748611
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439693-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06439693)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Breast Cancer.\nStudy: The SAPPHO St
 udy: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic B
 reast Cancer\nEstimated primary completion: 30 March 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06439693
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257993-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT05257993)
DESCRIPTION:Nab-paclitaxel\, phase 1/2.\nStudy: Study to Assess the Safety\
 , Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemci
 tabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pan
 creatic Cancer\nEstimated primary completion: April 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05257993
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692738-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06692738)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemothera
 py for First-Line Treatment of Locally Advanced or Metastatic Squamous Non
 -small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 1 July 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06692738
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155629-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07155629)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Neoadjuvant Treatment vs Upfr
 ont Surgery for Left-Sided Pancreatic Cancer\nEstimated primary completion
 : 31 August 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab
 -paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07155629
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer
 .\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment
  Combinations in Patients With Metastatic or Locally Advanced Breast Cance
 r\nEstimated primary completion: 30 September 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04858009-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04858009)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Hyperthermic Intraperitoneal 
 Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metasta
 sis\nEstimated primary completion: 30 September 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04858009
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07096362-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07096362)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Utility of ctDNA in Early Swi
 tch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcin
 oma\nEstimated primary completion: 30 September 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07096362
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109402-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06109402)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable N
 on-small Cell Lung Cancer\nEstimated primary completion: 1 November 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06109402
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07763496-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07763496)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Relacorilant and Nab-Paclitax
 el in Recurrent or Metastatic Cervical Cancer\nEstimated primary completio
 n: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab
 -paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07763496
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07865910-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07865910)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy
 : A Study to Learn the Safety and Efficacy of HLX37 in Combination With Ch
 emotherapy for First-line Treatment in Adult Participants With Locally Adv
 anced or Metastatic Non-Small Cell Lung Cancer\nEstimated primary completi
 on: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07865910
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04589234-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04589234)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Saltikva for Metastatic Pancr
 eatic Cancer\nEstimated primary completion: 31 December 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04589234
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981014-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT05981014)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Breast Cancer.\nStudy: Study of Au
 tologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Ther
 apy for HER2-Negative Breast Cancer\nEstimated primary completion: 31 Dece
 mber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclit
 axel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05981014
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371611-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07371611)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Sintilimab Plus Chemotherapy 
 as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous C
 ell Carcinoma\nEstimated primary completion: 31 December 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07371611
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07628062-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07628062)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Phase 2 Study of NAI\, HPV Va
 ccine\, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed b
 y De-Intensified Radiation Compared With Standard Chemoradiation\nEstimate
 d primary completion: 31 December 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07628062
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318883-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07318883)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy
 : A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serp
 lulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or
  Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamo
 us Non-Small Cell Lung Cancer\nEstimated primary completion: January 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07318883
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05919537-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20310301
DTEND;VALUE=DATE:20310302
SUMMARY:Nab-paclitaxel: Phase 1 readout est. (NCT05919537)
DESCRIPTION:Nab-paclitaxel\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: 
 Study of an Anti-HER3 Antibody\, HMBD-001\, With or Without Chemotherapy i
 n Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation\nEs
 timated primary completion: 1 March 2031. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05919537
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06288373-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20310301
DTEND;VALUE=DATE:20310302
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT06288373)
DESCRIPTION:Nab-paclitaxel\, phase 2/3.\nStudy: Neoadjuvant Chemoimmunother
 apy Versus Concurrent Chemoradiotherapy for LACC\nEstimated primary comple
 tion: 1 March 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 ab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06288373
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06861777-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT06861777)
DESCRIPTION:Nab-paclitaxel\, phase 2/3.\nStudy: Total Neoadjuvant Therapy C
 ombined With Adebrelimab in Locally Advanced Resectable ESCC\nEstimated pr
 imary completion: May 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06861777
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783140-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20310602
DTEND;VALUE=DATE:20310603
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT06783140)
DESCRIPTION:Nab-paclitaxel\, phase 2/3.\nStudy: Study of NABPLAGEM vs. Nab-
 Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer\nEstimated pr
 imary completion: 2 June 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06783140
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063745-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20310812
DTEND;VALUE=DATE:20310813
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07063745)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy
 : A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pe
 mbrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemoth
 erapy in First-line Metastatic Non-small Cell Lung Cancer Participants Wit
 h Homozygous MTAP Deletion\nEstimated primary completion: 12 August 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07063745
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752394-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20310823
DTEND;VALUE=DATE:20310824
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07752394)
DESCRIPTION:Nab-paclitaxel\, phase 2.\nStudy: Penpulimab Combined With Chem
 otherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma\nEsti
 mated primary completion: 23 August 2031. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07752394
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06837948-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20311201
DTEND;VALUE=DATE:20311202
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06837948)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclon
 al Antibody in Locally Advanced NSCLC\nEstimated primary completion: 1 Dec
 ember 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pacli
 taxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06837948
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629817-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20320315
DTEND;VALUE=DATE:20320316
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07629817)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Surgery vs. Radical Chemoradi
 otherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy\nEstimate
 d primary completion: 15 March 2032. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07629817
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839676-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Nab-paclitaxel: Phase na readout est. (NCT07839676)
DESCRIPTION:Nab-paclitaxel\, phase na.\nStudy: A Prospective Study of Concu
 rrent Hyperthermia\, Chemotherapy and Radiotherapy in Borderline and Local
 ly Advanced Pancreatic Cancer (PANHEAT)\nEstimated primary completion: 31 
 March 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pacli
 taxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07839676
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981001-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT05981001)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer
 .\nStudy: Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocyte
 s for Advanced HER2-Negative Breast Cancer\nEstimated primary completion: 
 30 April 2032. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pa
 clitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05981001
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827872-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20321001
DTEND;VALUE=DATE:20321002
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07827872)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Neoadjuvant Sintilimab Plus C
 hemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma\nEstimated primary co
 mpletion: 1 October 2032. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07827872
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06714604-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06714604)
DESCRIPTION:Nab-paclitaxel\, phase 3.\nStudy: Standard or Prolonged Neoadju
 vant Chemotherapy Before Surgery for BR/LAPC\nEstimated primary completion
 : 31 December 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 ab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06714604
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keyt
 ruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexa
 valent OX40 Agonist)\nEstimated primary completion: July 2033. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877584-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20331130
DTEND;VALUE=DATE:20331201
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07877584)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line 
 Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%\nEstimate
 d primary completion: 30 November 2033. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07877584
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863999-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20331201
DTEND;VALUE=DATE:20331202
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07863999)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined
  With Monoclonal Antibody in Locally Advanced NSCLC\nEstimated primary com
 pletion: 1 December 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07863999
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096844-1963@assetmemo.bio
DTSTAMP:20261121T004940Z
DTSTART;VALUE=DATE:20390401
DTEND;VALUE=DATE:20390402
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06096844)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Ol
 der Adults With Stage IIIB-IV Lung Cancer\, The ACHIEVE Trial\nEstimated p
 rimary completion: 1 April 2039. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06096844
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
